Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 1 min 54 sec ago

CutisPharma Appoints Neal Muni, MD, MSPH as President

Tue, 07/15/2014 - 13:10
WILMINGTON, Mass., July 15, 2014 -- (Healthcare Sales & Marketing Network) -- CutisPharma announced today that it has appointed Neal Muni, MD, MSPH as President and member of the Board of Directors. Dr. Muni will assume responsibility for overseeing the c...
Biopharmaceuticals, Personnel
CutisPharma

Mystic Pharmaceuticals Unveils The Next Generation Of Patient-Centric Sublingual Drug Delivery Devices

Tue, 07/15/2014 - 13:05
AUSTIN, Texas--(Healthcare Sales & Marketing Network)--Mystic Pharmaceuticals, Inc. today announced the availability of its Javelin Sublingual™ drug delivery devices. Javelin Sublingual dispensers utilized Mystic’s VersiDoser® and VRx2™ platform techno...
Biopharmaceuticlas, Drug Delivery, Product Launch
Mystic Pharmaceuticals, Javelin Sublingual, VersiDoser, VRx2

Pradaxa(R) (dabigatran etexilate) Now Available in the UK for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Prevention of Recurrence

Tue, 07/15/2014 - 12:59
Pradaxa® is as effective as warfarin in the treatment and secondary prevention of DVT and PE with significantly fewer major, or clinically relevant non-major bleeds, compared to warfarin1,2 BRACKNELL, England, July 15, 2014 -- (Healthcare Sales & Ma...
Biopharmaceuticals, Regulatory
Boehringer Ingelheim, Pradaxa, dabigatran, DVT, Pulmonary Embolism

FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer

Tue, 07/15/2014 - 12:44
SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics Lic...
Biopharmaceuticals, Oncology, FDA
Genentech, Roche Group, Avastin, bevacizumab, cervical cancer

Boston Scientific Receives CE Mark For Ranger(TM) Drug-Coated Balloon

Mon, 07/14/2014 - 16:04
Innovative Technology Strengthens Company's Leading Portfolio of Solutions for Peripheral Vascular Disease MARLBOROUGH, Mass., July 14, 2014 -- (Healthcare Sales & Marketing Network) -- Demonstrating its continued leadership in the development of innov...
Devices, Interventional, Regulatory
Boston Scientific, Ranger, Paclitaxel-Coated PTA Balloon

Intact Vascular, Inc. Hires Bruce Shook as President and Chief Executive Officer

Mon, 07/14/2014 - 16:01
WAYNE, Pa.--(Healthcare Sales & Marketing Network)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Bruce J. Shook is joining the Company as President and Chief Executive Off...
Devices, Interventional, Personnel
Intact Vascular, Tack-It Endovascular System

MYOS Corporation Appoints World Renowned Scientific Visionary and Entrepreneur, J. Craig Venter, Ph.D., to Board of Directors

Mon, 07/14/2014 - 15:39
Drs. Venter, Hariri and Diamandis United in Another Ground-Breaking Biotechnology Enterprise CEDAR KNOLLS, NJ--(Healthcare Sales & Marketing Network) - MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherape...
Biopharmaceuticals, Personnel
MYOS Corp, Fortetropin, myostatin inhibitor

Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction

Mon, 07/14/2014 - 13:01
Brings Differentiated, Attractive Product Portfolio and Enhanced Commercial Platform, Diversifying Mylan's Business and Adding New Sales Channels in Acquired Markets Immediately and Significantly Accretive to Earnings, with Opportunity to Accelerate Tar...
Biopharmaceuticals, Generics, Acquisitions
Mylan, Abbott

Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan

Mon, 07/14/2014 - 12:54
ABBOTT PARK, Ill., July 14, 2014 (Healthcare Sales & Marketing Network) -- Abbott (ABT) announced today that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combi...
Biopharmaceuticals, Generics, Acquisitions
Abbott, Mylan

MGC Diagnostics Corporation Completes Agreement to Acquire Medisoft SA

Mon, 07/14/2014 - 12:48
Positions MGCD as a global leader in Cardiorespiratory diagnostic products SAINT PAUL, Minn., July 14, 2014 -- (Healthcare Sales & Marketing Network) -- MGC Diagnostics Corporation (MGCD), a leading global medical technologies company, today announced ...
Diagnostics, Mergers & Acquisitions
MGC Diagnostics, Medisoft SA

Titan Spine Receives FDA Clearance to Launch Endoskeleton(R) TL Device for Lateral Spinal Fusion

Mon, 07/14/2014 - 12:41
First Surgeries Conducted by Kade Huntsman, M.D. MEQUON, Wis.--(Healthcare Sales & Marketing Network)--Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants, today announced that it ha...
Devices, Neurosurgery, Orthopaedic, FDA
Titan Spine, Endoskeleton TL, lateral fusion device, spine surgery

Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf(R) (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening

Mon, 07/14/2014 - 12:32
Data from the coBRIM study will be presented at an upcoming medical meeting Genentech plans to submit these data to the U.S. Food and Drug Administration (FDA) SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member...
Biopharmaceuticals, Oncology
Genentech, Roche Group, cobimetinib, Zelboraf, melanoma, MEK inhibitor

Transition Therapeutics Appoints Carl Damiani as Chief Operating Officer

Fri, 07/11/2014 - 12:41
TORONTO , July 11, 2014 (Healthcare Sales & Marketing Network) - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) Chairman and Chief Executive Officer, Dr. Tony Cruz is pleased to announce that Carl ...
Biopharmaceuticals, Personnel
Transition Therapeutics

Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1

Fri, 07/11/2014 - 12:34
Ipsen and Galderma to expand their current distribution agreement for Dysport®/Azzalure® in aesthetic and dermatology indications to the US and Canada Ipsen and Galderma to collaborate on development and commercialization of new neurotoxins, inc...
Biopharmaceuticals, Dermatology, Distribution
Ipsen, Galderma, Dysport, Azzalure

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong